LCI699C2301, entitled " A Phase III, Multi-Center Double-Blind, Randomized, Withdrawal Study of LCI699 Following a 24 Week, Single-Arm, Open-Label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patie

Project: Research project

Project Details

StatusFinished
Effective start/end date6/20/14 → 6/30/20

Funding

  • Novartis Pharmaceuticals Corporation (LCI699C2301)